← All Alto Neuroscience, INC filings

Alto Neuroscience, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
ANRO
Alto Neuroscience, INC
10-K: Alto Neuroscience Reports Mixed Clinical Results, Secures Funding
Alto Neuroscience's 2025 annual report highlights progress in its precision psychiatry pipeline with new funding, despite a setback in its ALTO-100 MDD trial.
NYSE
ANRO
Alto Neuroscience, INC
10-K: Alto Neuroscience Reports 2024 Results, Highlights Clinical Pipeline Progress
Alto Neuroscience's 2024 10-K filing details the company's financial status, clinical trial updates, and strategic direction in precision psychiatry.
NYSE
ANRO
Alto Neuroscience, INC
10-K: Alto Neuroscience Details Stock Structure and Regulatory Compliance in 10-K Filing
Alto Neuroscience's 10-K filing outlines the company's stock authorization, preferred stock details, warrant agreements, and compliance with securities regulations.